HCV

Hepatitis C virus

Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle.NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells.

The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death.

The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme.

The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.

HCV Inhibitors & Agonists

2',5-Difluoro-2'-deoxycytidine

Cat. No.: HY-129057

2',5-Difluoro-2'-deoxycytidine, compound 13, has potent anti-**HCV** activity and toxicity to ribosomal RNA (**rRNA**).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

2'-O-Methylcytidine

Cat. No.: HY-W011834

2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of **HCV replication**.
2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 100 mg

4-Phenoxybenzylamine

Cat. No.: HY-18563

4-Phenoxybenzylamine inhibits the function of the **NS3** protein by stabilizing an inactive conformation with an IC_{50} of about 500 μM against FL NS3/4a.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

ABT-072

Cat. No.: HY-101634

ABT-072 is an orally active and potent non-nucleoside HCV **NS5B polymerase** inhibitor (HCV GT1a EC_{50}=1 nM; HCV GT1b EC_{50}=0.3 nM).



Purity: 99.86%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ABT-072 potassium trihydrate

Cat. No.: HY-101634A

ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV **NS5B polymerase** inhibitor (HCV GT1a EC_{50}=1 nM; HCV GT1b EC_{50}=0.3 nM).



Purity: 99.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ACH-806

(GS9132)

Cat. No.: HY-19512

ACH-806 is an **NS4A** antagonist which can inhibit Hepatitis C Virus (**HCV**) replication with an EC_{50} of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255)

Cat. No.: HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM.
AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alisporivir

(Debio-025; DEB-025)

Cat. No.: HY-12559

Alisporivir (Debio-025) is a **cyclophilin** inhibitor molecule with potent anti-hepatitis C virus (**HCV**) activity.



Purity: 98.15%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Anguizole

Cat. No.: HY-13321

Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Artemisinin

(Qinghaosu; NSC 369397) Cat. No.: HY-B0094

Artemisinin (Qinghaosu), a sesquiterpene lactone, is an **anti-malarial** drug isolated from the aerial parts of Artemisia annua L. plants. Artemisinin inhibits AKT signaling pathway by decreasing **pAKT** in a dose-dependent manner.



Purity: 99.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Artemisinin-d4

(Qinghaosu-d4; NSC 369397-d4) Cat. No.: HY-B0094S1

Artemisinin-d4 (Qinghaosu-d4) is the deuterium labeled Artemisinin. Artemisinin (Qinghaosu), a sesquiterpene lactone, is an **anti-malarial** drug isolated from the aerial parts of Artemisia annua L. plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ASP5286

Cat. No.: HY-P3351

ASP5286 is a novel non-immunosuppressive **cyclophilin** inhibitor for the treatment of HCV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Asunaprevir

(BMS-650032) Cat. No.: HY-14434

Asunaprevir (BMS-650032) is a potent and orally bioavailable **hepatitis C virus (HCV) NS3 protease** inhibitor, with IC_{50} of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Azvudine

(RO-0622; FNC) Cat. No.: HY-19314

Azvudine (RO-0622) is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**. Azvudine exerts highly potent inhibition on HIV-1 (EC_{50}s ranging from 0.03 to 6.92 nM) and HIV-2 (EC_{50}s ranging from 0.018 to 0.025 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azvudine hydrochloride

(RO-0622 hydrochloride; FNC hydrochloride) Cat. No.: HY-19314A

Azvudine (RO-0622) hydrochloride is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Balapiravir

(Ro 4588161; R1626) Cat. No.: HY-10443

Balapiravir (Ro 4588161; R1626) is an orally active prodrug of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-**HCV** activity.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Balapiravir hydrochloride

(Ro 4588161 hydrochloride; R1626 hydrochloride) Cat. No.: HY-10443A

Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active prodrug of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-**HCV** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beclabuvir

(BMS-791325) Cat. No.: HY-12429

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (**HCV**) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC_{50} of < 28 nM. .



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bemnifosbuvir

(AT-511) Cat. No.: HY-137958A

Bemnifosbuvir (AT-511) is a potent and orally active **HCV viral replication** inhibitor. Bemnifosbuvir is highly effective in the control of **SARS-CoV-2 (COVID-19)** infection in vitro (EC_{90}=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Bemnifosbuvir hemisulfate

(AT-527) Cat. No.: HY-137958

Bemnifosbuvir hemisulfate (AT-527), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active **HCV viral replication** inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of **SARS-CoV-2 (COVID-19)** infection in vitro (EC_{90}=0.47 μM).



Purity: 99.33%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

BLT-1

(Block lipid transport-1) Cat. No.: HY-116767

BLT-1, a thiosemicarbazone copper chelator, is a selective **scavenger receptor B, type 1 (SR-BI)** inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-986094

(INX-08189) Cat. No.: HY-13337

BMS-986094 (INX-08189) is a potent inhibitor of **hepatitis C virus (HCV)** replication, with an EC_{50} of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986144

Cat. No.: HY-131905S

BMS-986144 is a third-generation, pan-genotype (GT) **NS3/4A protease** inhibitor. BMS-986144 inhibits HCV replicon with EC_{50}s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boceprevir

(EBP 520; SCH 503034) Cat. No.: HY-10237

Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with a K_i of 14 nM in both enzyme assay and an EC_{90} of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 97.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Boceprevir-d9

(EBP 520-d9; SCH 503034-d9) Cat. No.: HY-10237S

Boceprevir-d9 (EBP 520-d9) is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with a K_i of 14 nM in both enzyme assay and an EC_{90} of 350 nM in cell-based replicon assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Celgosivir

(MBI 3253; MDL 28574; MX3253) Cat. No.: HY-16134

Celgosivir (MBI 3253; MDL 28574; MX3253) is an **α-glucosidase I** inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC_{50} of 1.27 μM in in vitro assay.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride)

Cat. No.: HY-16134A

Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an **α-glucosidase I** inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC_{50} of 1.27 μM in in vitro assay.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Ciluprevir

(BILN 2061; BILN 2061ZW) Cat. No.: HY-10242

Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the **HCV NS3 protease** with an IC_{50} of 3.0 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Lomibuvir

(cis-VX-222) Cat. No.: HY-114571

cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the **HCV NS5B polymerase (RdRp)** with a K_d of 17 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clemizole

Cat. No.: HY-30234

Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole is an inhibitor of **TRPC5 channel**. The IC_{50} of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its EC_{50} for viral replication is 8 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Clemizole hydrochloride

Cat. No.: HY-30234A

Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole hydrochloride is an inhibitor of **TRPC5 channel**.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Coblopasvir

(KW-136)

Cat. No.: HY-117411

Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A **(NS5A)** inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coblopasvir dihydrochloride

(KW-136 dihydrochloride)

Cat. No.: HY-117411A

Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A **(NS5A)** inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyclophilin inhibitor 1

Cat. No.: HY-112712

Cyclophilin inhibitor 1 is a potent and orally bioavailable **cyclophilin A** inhibitor, with a K_d of 5 nM, shows effective anti-**HCV** activity, with an EC_{50} of 98 nM for HCV 2a.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclophilin inhibitor 3

Cat. No.: HY-146648

Cyclophilin inhibitor 3 (compound 7c) is a potent **cyclophilin A (CypA)** inhibitor with an potent anti-HCV activity (EC_{50} of 4.2 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daclatasvir

(BMS-790052; EBP 883)

Cat. No.: HY-10466

Daclatasvir (BMS-790052) is a potent and orally active **HCV NS5A protein** inhibitor with EC_{50}s range of 9-146 pM for **multiple HCV replicon genotypes**.



Purity: 99.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Daclatasvir dihydrochloride

(BMS-790052 dihydrochloride; EBP 883 dihydrochloride)

Cat. No.: HY-10465

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active **HCV NS5A protein** inhibitor with EC_{50}s range of 9-146 pM for **multiple HCV replicon genotypes**.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Daclatasvir-d16

(BMS-790052-d16; EBP 883-d16)

Cat. No.: HY-10466S2

Daclatasvir-d16 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daclatasvir-d6

(BMS-790052-d6; EBP 883-d6)

Cat. No.: HY-10466S

Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Danoprevir

(ITMN-191; R7227; RO5190591; RG7227) Cat. No.: HY-10238

Danoprevir (ITMN-191) is an orally active **NS3/4A protease** inhibitor for hepatitis C virus (HCV) with an IC_{50} of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC_{50} higher than 10 μM).



Purity: 98.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dasabuvir

(ABT-333) Cat. No.: HY-13998

Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the **HCV NS5B** gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC_{50} between 2.2 and 10.7 nM.



Purity: 98.40%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dasabuvir-d6

(ABT-333-d6) Cat. No.: HY-13998S

Dasabuvir-d6 (ABT-333-d6) is the deuterium labeled Dasabuvir.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DDX3-IN-1

Cat. No.: HY-121832

DDX3-IN-1 (Compound 16f) is a DEAD-box polypeptide 3 (**DDX3**) inhibitor with CC_{50}s of 50 and 36 μM for **HIV** and **HCV**, respectively. Antiviral activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deapioplatycodin D

Cat. No.: HY-N0588

Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity.



Purity: 97.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Deferiprone

Cat. No.: HY-B0568

Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Deferiprone-d3

Cat. No.: HY-B0568S

Deferiprone-d3 is the deuterium labeled Deferiprone. Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload.



Purity: >98%
Clinical Data:
Size: 5 mg, 50 mg

Dehydrojuncusol

Cat. No.: HY-N8188

Dehydrojuncusol, a potent **HCV** inhibitor, targets **HCV NS5A** and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Deleobuvir

(BI 207127) Cat. No.: HY-12634

Deleobuvir (BI 207127) is a potent non-nucleoside **hepatitis C virus (HCV) NS5B polymerase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EIDD-1931

(β-D-N4-hydroxycytidine; NHC) Cat. No.: HY-125033

EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent **anti-virus agent**. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Elbasvir

(MK-8742) Cat. No.: HY-15789

Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (**HCV NS5A**) inhibitor with **EC_{50}**s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.



Purity: 98.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

FGI-106

Cat. No.: HY-124618

FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with **EC_{50}**s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGI-106 tetrahydrochloride

Cat. No.: HY-124618A

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with **EC_{50}**s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Filibuvir

Cat. No.: HY-10118

Filibuvir is an orally active, selective non-nucleoside inhibitor of the **HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp)**. Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B.



Purity: 98.19%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

FNC-TP

Cat. No.: HY-139262

FNC-TP is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FNC-TP trisodium

Cat. No.: HY-139262A

FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furaprofen

(R803) Cat. No.: HY-U00213

Furaprofen (R803) is an effective **HCV replication** inhibitor. Furaprofen (R803) is substantially more potent against genotype **1a** and **1b** replicons (**EC_{50}**, ~30 nM) than against the genotype 2a replicon (EC_{50}, ~1,000 nM).



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg

Gentiopicroside

(Gentiopicrin) Cat. No.: HY-N0494

Gentiopicroside, a naturally occurring iridoid glycoside, inhibits **P450** activity, with an IC_{50} and a K_i of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has antianti-inflammatoryand antioxidative effects.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Glecaprevir

(ABT-493) Cat. No.: HY-17634

Glecaprevir is a novel **HCV NS3/4A protease** inhibitor, with **IC_{50}** values ranging from 3.5 to 11.3 nM. Glecaprevir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 4.09 μM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Grazoprevir

(MK-5172) Cat. No.: HY-15298

Grazoprevir (MK-5172) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with **K_i**s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir hydrate

(MK-5172 hydrate) Cat. No.: HY-15298B

Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir potassium salt

(MK-5172 potassium salt) Cat. No.: HY-15298A

Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.40%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir sodium salt

(MK-5172 sodium salt) Cat. No.: HY-15298C

Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

GS-443902

(GS-441524 triphosphate; Remdesivir metabolite) Cat. No.: HY-126303

GS-443902 (GS-441524 triphosphate) is a potent viral **RNA-dependent RNA-polymerases (RdRp)** inhibitor with IC_{50}s of 1.1 μM, 5 μM for **RSV** RdRp and **HCV** RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GS-443902 trisodium (GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium)

Cat. No.: HY-126303C

GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral **RNA-dependent RNA-polymerases (RdRp)** inhibitor with IC_{50}s of 1.1 μM, 5 μM for **RSV** RdRp and **HCV** RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).



Purity: 99.98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GSK-A1

Cat. No.: HY-125118

GSK-A1 is a selective **type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)** inhibitor with a **pIC**$_{50}$ of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC_{50} of about 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK8175

(GSK2878175) Cat. No.: HY-112047

GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-29

Cat. No.: HY-136266

HCV-IN-29 is a hepatitis C virus **(HCV)** inhibitor exacted from patent US8329159B2, compound 1e.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-3

Cat. No.: HY-18564

HCV-IN-3 is a **hepatitis C virus (HCV) NS3/4a** protein inhibitor, with an IC_{50} of 20 μM, a K_d of 29 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-30

Cat. No.: HY-136267

HCV-IN-30 (compound 48) is a **HCV NS5A** replication complex inhibitor, with IC_{50}s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-31

Cat. No.: HY-138305

HCV-IN-31 (compound 4) is a **HCV** inhibitor, with an EC_{50}/EC_{95} of 15.7 μM for HCV replicon.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HCV-IN-33

Cat. No.: HY-144106

HCV-IN-33 (Compound (S)-3i) is an **HCV** entry inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-38

Cat. No.: HY-115989

HCV-IN-38 is a potent, selective and orally active **HCV** inhibitor (EC_{50}=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-4

Cat. No.: HY-P0162

HCV-IN-4 is a potent and orally active **HCV NS5A** inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC_{90}s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-7

Cat. No.: HY-133018

HCV-IN-7 is an orally active and potent **pan-genotypic HCV NS5A** inhibitor with IC_{50}s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HCV-IN-7 hydrochloride

Cat. No.: HY-133018A

HCV-IN-7 hydrochloride is an orally active and potent **pan-genotypic HCV NS5A** inhibitor with IC_{50}s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hepatitis Virus C NS3 Protease Inhibitor 2

Cat. No.: HY-P2502

Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of **hepatitis C virus (HCV) NS3 protease**, with a K_i of 41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Honokiol

(NSC 293100)

Cat. No.: HY-N0003

Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of **Akt**.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

IDX184

Cat. No.: HY-19558

IDX184 is a potent and orally bioavailable inhibitor of **HCV replication**. IDX184 potently inhibits **HCV polymerase** (IC_{50}=0.31 μM, K_i=52.3 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IMB-26

Cat. No.: HY-115988

IMB-26 is a **HCV** inhibitor with an EC_{50} of 2.1 μM. IMB-26 shows potent an anti-HCV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inarigivir soproxil

(SB9200; GS-9992) Cat. No.: HY-109035

Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant **HCV** variants, with EC_{50}s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ITX5061

Cat. No.: HY-19900

ITX5061 is a type II inhibitor of **p38 MAPK** and also an antagonist of **scavenger receptor B1** (**SR-B1**).



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

JTK-853

Cat. No.: HY-19921

JTK-853 is a novel, non-nucleoside **Hepatitis C Virus** (**HCV**) **polymerase** inhibitor which shows effective antiviral activity in **HCV replicon** cells with EC_{50}s of 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

KIN101

Cat. No.: HY-126113

KIN101 is a potent **RNA viral** inhibitor with IC_{50}s of 2 μM, >5 μM for **influenza virus** and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of **IRF-3** dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KIN1408

Cat. No.: HY-19961

KIN1408 is an agonist of the **RIG-1-like receptor (RLR) pathway** and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against **HCV**, **influenza A**, **dengue virus 2**, **Ebola**, **Nipah**, and **Lassa viruses**.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ledipasvir

(GS-5885) Cat. No.: HY-15602

Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50}s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a **SARS-CoV** $3CL^{pro}$ inhibitor with an IC_{50} of 1.62 μM.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir (acetone)

(GS-5885 acetone) Cat. No.: HY-15602A

Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir (diacetone)

(GS-5885 diacetone) Cat. No.: HY-15602D

Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ledipasvir D-tartrate

(GS-5885 D-tartrate) Cat. No.: HY-15602B

Ledipasvir D-tartrate is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: 96.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir-d6

(GS-5885-d6) Cat. No.: HY-15602S

Ledipasvir-d6 (GS-5885-d6) is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50}s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lomibuvir

(VX-222) Cat. No.: HY-75800

Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the **HCV NS5B polymerase (RdRp)** with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 **HCV** subgenomic replicon with an EC_{50} of 5.2 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mecarbinate

(Dimecarbin; Dimecarbine; Dimekarbin) Cat. No.: HY-B0376

Mecarbinate is an anti-hepatitis C virus (HCV) agent.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Mericitabine

(RG 7128; R-7128; PSI 6130 diisobutyrate) Cat. No.: HY-10240

Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.



Purity: 99.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Merimepodib

(VX-497; MMPD) Cat. No.: HY-13986

Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (**IMPDH**) with broad spectrum antiviral activities.



Purity: 98.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Micrococcin P1

Cat. No.: HY-125728

Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent **hepatitis C virus (HCV)** inhibitor with an EC_{50} range of 0.1-0.5 μM. Micrococcin P1 has in vitro antibacterial activity against Gram-positive **bacterial** strains. The MIC values of Micrococcin P1 against **S.**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Mizoribine

(NSC 289637; HE 69) Cat. No.: HY-17470

Mizoribine (NSC 289637), an imadazole nucleoside, inhibits **HCV** RNA replication with IC_{50} of approximately 100 μM for anti-HCV activity. Immunosuppressant.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

MK-0608

Cat. No.: HY-10244

MK-0608 is a potent and orally bioavailable inhibitor of **HCV replication** in vitro with an EC_{50} of 0.3 μM (EC_{90}=1.3 μM) in the subgenomic-replicon assay.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Monodes(N-carboxymethyl)valine Daclatasvir

(Daclatasvir Impurity A) Cat. No.: HY-133246

Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Mulberroside C

Cat. No.: HY-N0620

Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.). Mulberroside C is a **HCV replicon** inhibitor. Antiviral activity.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Myriocin

Cat. No.: HY-N6798

Myriocin, a fungal metabolite isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of **serine-palmitoyl-transferase (SPT)** and a key enzyme in de novo synthesis of sphingolipids.

Purity: 100.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Narlaprevir

(SCH 900518) Cat. No.: HY-10300

Narlaprevir (SCH 900518) is a selective and orally bioavailable **NS3 protease** inhibitor with a K_i value of 6 nM and an EC_{90} value of 40 nM. Narlaprevir also inhibits the **HCV nonstructural protein 3 serine protease**.



Purity: 98.15%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nesbuvir

(HCV-796) Cat. No.: HY-14775

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (**HCV**) nonstructural protein 5B (**NS5B**) polymerase.



Purity: 98.83%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NHC-diphosphate

Cat. No.: HY-135867D

NHC-diphosphate is an active phosphorylated intracellular **metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC is a pyrimidine ribonucleoside and behaves as a potent **anti-virus agent**.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NHC-diphosphate triammonium

Cat. No.: HY-135867F

NHC-triphosphate triammonium is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NHC-triphosphate

Cat. No.: HY-135867

NHC-triphosphate is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the **viral polymerase** and can be incorporated into **HCV** replicon RNA.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg

NHC-triphosphate tetraammonium

Cat. No.: HY-135867E

NHC-triphosphate tetraammonium is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form.



Purity: 96.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NHC-triphosphate tetrasodium

Cat. No.: HY-135867A

NHC-triphosphate tetrasodium is an active phosphorylated **intracellular metabolite** of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NIM811

((Melle-4)cyclosporin; SDZ NIM811) Cat. No.: HY-P0025

NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable **mitochondrial permeability transition** and **cyclophilin** dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .



Purity: 98.82%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

NM107

(2'-C-Methylcytidine; NM-107) Cat. No.: HY-10468

NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the **hepatitis C virus (HCV) NS5B polymerase**, the EC_{50} of NM107 in the wild-type replicon cells is 1.85 μM.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nucleoside-Analog-1

Cat. No.: HY-77651

Nucleoside-Analog-1 is a 4'-Azidocytidine analogue against Hepatitis C virus replication.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Nucleoside-Analog-2

Cat. No.: HY-77652

Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (**HCV**) replication.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Oenothein B

Cat. No.: HY-N7765

Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of **poly(ADP-ribose) glycohydrolase**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Oglufanide

(H-Glu-Trp-OH; L-Glutamyl-L-tryptophan)

Cat. No.: HY-13718

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits **vascular endothelial growth factor (VEGF)**. Oglufanide can stimulate the immune response to **hepatitic C virus (HCV)** and intracellular bacterial infections.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ombitasvir

(ABT-267)

Cat. No.: HY-13997

Ombitasvir is a potent inhibitor of the **hepatitis C virus protein NS5A**, with EC_{50}s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Paritaprevir

(ABT-450; Veruprevir)

Cat. No.: HY-12594

Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (**NS3/4A**) protease inhibitor with EC_{50}s of 1 and 0.21 nM against **HCV** 1a and 1b, respectively. Paritaprevir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 1.31 μM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Peretinoin

(NIK333)

Cat. No.: HY-100008

Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as **retinoid X receptor (RXR)** and **retinoic acid receptor (RAR)**.

Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Platycodin D3

Cat. No.: HY-N3519

Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-**HCV** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSI-352938

(PSI-938)

Cat. No.: HY-15231

PSI-352938 (PSI-938) is a hepatitis C virus (**HCV**) nucleotide inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

PSI-6130

(R 1656)

Cat. No.: HY-10165

PSI-6130 is a potent and selective inhibitor of **HCV NS5B polymerase**, and inhibits HCV replication with a mean IC_{50} of 0.6 μM. .



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

PSI-6206

(RO 2433; GS-331007)

Cat. No.: HY-15236

PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits **HCV replicon** with EC_{90} of >100 μM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PSI-6206 13C,d3 (RO-2433 13C,d3; GS-331007 13C,d3; Sofosbuvir metabolite GS-331007 13C,d3)

Cat. No.: HY-15236S

PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits **HCV replicon** with **EC_{90}** of >100 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PSI-7409

Cat. No.: HY-15745

PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of **HCV**.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSI-7409 tetrasodium

Cat. No.: HY-15745A

PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting **HCV NS5B polymerases**, with **IC_{50}**s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

PSI-7976

Cat. No.: HY-15005A

PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R-1479 (4'-Azidocytidine)

Cat. No.: HY-10444

R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (**RdRp**) of **HCV**. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (**IC_{50}**=1.28 μM).



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Resiquimod (R848; S28463)

Cat. No.: HY-13740

Resiquimod is a Toll-like receptor 7 and 8 (**TLR7/TLR8**) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mg, 25 mg, 50 mg, 100 mg

Resiquimod-d5 (R848-d5; S28463-d5)

Cat. No.: HY-13740S

Resiquimod-d5 (R848-d5) is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ribavirin (ICN-1229)

Cat. No.: HY-B0434

Ribavirin (ICN-1229) is an **antiviral** agent against a broad spectrum of viruses including **HCV**, **HIVI**, and **RSV**.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

RIG-1 modulator 1

Cat. No.: HY-107902

RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including **influenza virus**, **HBV**, **HCV** and **HIV** extracted from patent WO 2015172099 A1.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

RO-9187

Cat. No.: HY-10870

RO-9187 is a potent inhibitor of **HCV** virus replication with an **IC_{50}** of 171 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RO8191

(CDM-3008; RO4948191) Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.

Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Saikosaponin B2

Cat. No.: HY-N0248

Saikosaponin B2 is an active component from Bupleurum kaoi root, acts as an entry inhibitor against HCV infection. Anti-cancer activity.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Samatasvir

(IDX719; IDX18719) Cat. No.: HY-16784

Samatasvir (IDX71) is a potent, orally active **NS5A** inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with **EC_{50}**s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sennidin A

Cat. No.: HY-N6936

Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits **HCV NS3 helicase**, with an **IC_{50}** of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sennidin B

Cat. No.: HY-N6935

Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits **HCV NS3 helicase**, with an **IC_{50}** of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Setrobuvir

(ANA598) Cat. No.: HY-13247

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV **NS5B** polymerase inhibitor. ANA-598 inhibits both de novo **RNA synthesis** and primer extension, with **IC_{50}**s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 **RdRp** and induces RdRp inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simeprevir

(TMC435) Cat. No.: HY-10241

Simeprevir (TMC435) is an oral and potent **HCV NS3/4A protease** inhibitor with a **K_i** of 0.36 nM. Simeprevir inhibits HCV replication with an **EC_{50}** of 7.8 nM. Simeprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simeprevir-13C,d3

(TMC435-13C,d3) Cat. No.: HY-10241S

Simeprevir-13C,d3 (TMC435-13C,d3) is the 13C- and deuterium labeled Simeprevir. Simeprevir (TMC435) is an oral and potent **HCV NS3/4A protease** inhibitor with a **K_i** of 0.36 nM. Simeprevir inhibits HCV replication with an **EC_{50}** of 7.8 nM. Simeprevir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMCypI C31

Cat. No.: HY-125182

SMCypI C31 is a non-peptidic **cyclophilin** inhibitor with potent **peptidyl-prolyl cis/trans isomerases (PPIase)** inhibitory activity (**IC_{50}** of 0.1 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sofosbuvir

(GS-7977; PSI-7977) Cat. No.: HY-15005

Sofosbuvir (GS-7977) is an **HCV** RNA replication inhibitor with an **EC_{50}** of 92 nM.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Sofosbuvir 13CD3

(PSI-7977 13CD3; GS-7977 13CD3)

Cat. No.: HY-15005S

Sofosbuvir 13CD3 (PSI-7977 13CD3) is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sofosbuvir impurity A

Cat. No.: HY-15005C

Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity F

Cat. No.: HY-I0406

Sofosbuvir impurity F, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity H

Cat. No.: HY-I0938

Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity I

Cat. No.: HY-I0512

Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity J

Cat. No.: HY-I0975

Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity K

Cat. No.: HY-I0515

Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity L

Cat. No.: HY-I1196

Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity M

Cat. No.: HY-I0735

Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir impurity N

Cat. No.: HY-I0513

Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sofosbuvir-d6

(PSI-7977-d6; GS-7977-d6) Cat. No.: HY-15005S1

Sofosbuvir D6 (PSI-7977 D6) is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taribavirin

Cat. No.: HY-10545

Taribavirin is an orally active **inosine monophosphate dehydrogenase** inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taribavirin hydrochloride

Cat. No.: HY-10545A

Taribavirin hydrochloride is an orally active **inosine monophosphate dehydrogenase** inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 1 mg

Tegobuvir

(GS 333126; GS-9190) Cat. No.: HY-10544

Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Telaprevir

(VX-950) Cat. No.: HY-10235

Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease**, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.



Purity: 96.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Telaprevir-d4

(VX-950-d4) Cat. No.: HY-10235S

Telaprevir-d4 (VX-950-d4) is the deuterium labeled Telaprevir.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMC647055 Choline salt

Cat. No.: HY-15591A

TMC647055 choline salt is a cell-permeating, selective HCV NS5B inhibitor, eliciting a mean IC50 of 34 nM, as assessed in the RdRp primer-dependent transcription assay.



Purity: 98.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tris(4-aminophenyl)methane

(Leucopararosaniline) Cat. No.: HY-D0306

Tris(4-aminophenyl)methane is a triphenylmethane dye. Tris(4-aminophenyl)methane is a weak HCV helicase inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

TTP-8307

Cat. No.: HY-124806

TTP-8307 is a potent inhibitor of the replication of several **rhino- and enteroviruses**. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC_{50}=1.2 μM) and poliovirus by interfering with the synthesis of **viral RNA**. TTP-8307 exerts antiviral activity through oxysterol-binding protein **(OSBP)**.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

U18666A

Cat. No.: HY-107433

U18666A, an intra-cellular **cholesterol transport** inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus.



Purity: 95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

UK-1

Cat. No.: HY-129558

UK-1 is a cytotoxic metabolite from Streptomyces sp. 517-02 and exerts a wide spectrum of potent anticancer activities. UK-1 also inhibits HCV replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Uprifosbuvir

(IDX21437; MK-3682)

Cat. No.: HY-103487

Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valopicitabine

(NM283)

Cat. No.: HY-108060

Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable prodrug of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits **NS5B polymerase**, causing chain termination.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valopicitabine dihydrochloride

(NM283 dihydrochloride)

Cat. No.: HY-108060A

Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable prodrug of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits **NS5B** polymerase, causing chain termination.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vaniprevir

(MK-7009)

Cat. No.: HY-10243

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) **NS3/4A protease**.



Purity: 99.60%
Clinical Data: Launched
Size: 1 mg, 5 mg

VCH-916

Cat. No.: HY-13465

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase.



Purity: 99.51%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Velpatasvir

(GS-5816)

Cat. No.: HY-12530

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 2.16 μM.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Velpatasvir-d7

Cat. No.: HY-12530S

Velpatasvir-d7 (GS-5816-d7) is the deuterium labeled Velpatasvir. Velpatasvir (GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

Vesatolimod

(GS-9620)

Cat. No.: HY-15601

Vesatolimod (GS-9620) is a potent, selective and orally active agonist of **Toll-Like Receptor (TLR7)** with an **EC_{50}** of 291 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YM-53601

Cat. No.: HY-100313A

YM-53601, a **squalene synthase** inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an **IC_{50}** of 79 nM. Lipid-lowering agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-53601 free base

Cat. No.: HY-100313

YM-53601 free base, a **squalene synthase** inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC_{50} of 79 nM. Lipid-lowering agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ-Fagarine

Cat. No.: HY-N3918

γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-**HCV** activities with IC_{50} of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg